Replies to post #564496 on NorthWest Biotherapeutics Inc (NWBO)

[dstock07734]

HyGro,

By now you should know who is Dr. Mitchel Berger. In case you didn't, here is some info.
https://www.soc-neuro-onc.org/WEB/WEB/About_Content/Bios/Berger_Bio.aspx

Would Dr. Berger read the JAMA paper? Absolutely. Does he know Linda Liau well? Absolutely. Keep in mind Michael Weller from Switzerland has been funded by NWBO for many years.
https://www.tumorsection.org/files/304/

Keep in mind Michael Weller from Switzerland has been funded by NWBO for many years.

Does Dr. Berger know very well about the results from the combo trial by Linda Liau? Absolutely.

https://www.broadcastmed.com/neurology/8161/news/ucsf-s-dr-mitchel-berger-on-the-cancer-moonshot-relaunch

[Dr Bala]

NWBO has the most successful GBM trial and the therapy is sure to be approved by all the RAs. I am not near my laptop. Otherwise I would have linked an appropriate picture in connection with your post.

[biosectinvestor]

True, many trials do fail. But that appears unlikely to many experts and expert patient advocates so far With regard to DCVax-L and its Phase 3 results. The issue with the minor editorials you reference is that they are from doctors who have no familiarity with the treatment, they wrote in many instances basing their opinion on the false narratives that have been debunked but that remain out there (post hoc) and even that you repeat. Lastly, they meticulously avoided disclosing a consistent conflict of interest for all of them, connection to NVCR and Optune in a commercial manner likely to make them exceptionally wealthy. That was troubling, but consistent with what we have seen all the way along the way. That treatment has the most to lose from an effective, easy to comply with treatment that acts systematically.

Lastly, none of them said it WON’T be approved. And the world of medicine is free. They can put their heads in the sand and keep telling their patients NOT to save their tumor tissue for DCVax-L, and recommend the helmet, 18 hours a day, every day, for the time they have remaining, for life, at $21,000 per month forever. Sounds like a perverse prison sentence where you pay to be torture for as long as you’ve got and where any wish to rebel against wearing your cap just might or might not shorten your time and lead to you being blamed for this horrible disease.

I bet you one of two things will happen if DCVax-L is approved. They will either adapt and utilize it, or their clinics will slide in popularity very rapidly.

For all of the talk about the few letters and editorial, I expect they will adapt and be better doctors for it. For the chatter from these few doctors, I expect the worst part of it for them is that patients already want to freeze and store their tumors and they probably hate that because it foreshadows exactly what is going to happen to their prospering TTF businesses if DCVax-L succeeds. That must annoy them.

[jammy32]

I’ll not take the word of Adam Duckstein and stick with the oncologists that are extremely credentialed. Yes, I think that’s what mist here will do as as the lawsuit will show, some are financially motivated to lower the stock.

[Dr Bala]

But yet NWBO has the best GBM trial results in history and this therapy will surely be approved by all the RAs. Thanks so much, HyGro.

[CherryTree1]

You should take the word of the renounced experts, the giants in the field

Linda M. Liau, MD, PhD; Keyoumars Ashkan, MD, FRCP, FRCS; Steven Brem, MD; Jian L. Campian, MD, PhD; John E. Trusheim, MD;
Fabio M. Iwamoto, MD; David D. Tran, MD, PhD; George Ansstas, MD; Charles S. Cobbs, MD; Jason A. Heth, MD; Michael E. Salacz, MD;
Stacy D’Andre, MD; Robert D. Aiken, MD; Yaron A. Moshel, MD, PhD; Joo Y. Nam, MD; Clement P. Pillainayagam, MD; Stephanie A. Wagner, MD;
Kevin A. Walter, MD; Rekha Chaudhary, MD; Samuel A. Goldlust, MD; Ian Y. Lee, MD; Daniela A. Bota, MD, PhD; Heinrich Elinzano, MD; Jai Grewal, MD;
Kevin Lillehei, MD; Tom Mikkelsen, MD, FRCPC; Tobias Walbert, MD; Steven Abram, MD; Andrew J. Brenner, MD, PhD; Matthew G. Ewend, MD;
Simon Khagi, MD; Darren S. Lovick, MD; Jana Portnow, MD; Lyndon Kim, MD; William G. Loudon, MD; Nina L. Martinez, MD; Reid C. Thompson, MD;
David E. Avigan, MD; Karen L. Fink, MD, PhD; Francois J. Geoffroy, MD; Pierre Giglio, MD; Oleg Gligich, MD; Dietmar Krex, MD; Scott M. Lindhorst, MD;
Jose Lutzky, MD; Hans-Jörg Meisel, MD, PhD; Minou Nadji-Ohl, MD; Lhagva Sanchin, MD; Andrew Sloan, MD; Lynne P. Taylor, MD; Julian K. Wu, MD;
Erin M. Dunbar, MD; Arnold B. Etame, MD, PhD; Santosh Kesari, MD, PhD; David Mathieu, MD; David E. Piccioni, MD, PhD; David S. Baskin, MD;
Michel Lacroix, MD; Sven-Axel May, MD; Pamela Z. New, MD; Timothy J. Pluard, MD; Steven A. Toms, MD; Victor Tse, MD; Scott Peak, MD;
John L. Villano, MD, PhD; James D. Battiste, MD, PhD; Paul J. Mulholland, MD; Michael L. Pearlman, MD; Kevin Petrecca, MD, PhD;
Michael Schulder, MD; Robert M. Prins, PhD; Alton L. Boynton, PhD; Marnix L. Bosch, PhD

file:///C:/Users/351293897/Downloads/jamaoncology_liau_2022_oi_220066_1674054620.80001.pdf

instead of a handful of phonies with undisclosed conflicts of interest.